Lipigo 10 Tablet contains Rosuvastatin 10 mg, a potent lipid-lowering agent belonging to the statin class of medications. It is primarily indicated for the treatment of hypercholesterolemia and mixed dyslipidemia, helping to reduce elevated levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), and triglycerides, while modestly increasing high-density lipoprotein cholesterol (HDL-C). Rosuvastatin acts by selectively inhibiting HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to decreased cholesterol production in the liver and increased clearance of LDL-C from the bloodstream. Lipigo 10 is prescribed as part of a comprehensive lipid management plan that includes diet, exercise, and lifestyle modifications to reduce the risk of cardiovascular events such as myocardial infarction, stroke, and peripheral arterial disease in patients with atherosclerotic cardiovascular disease or multiple risk factors. The 10 mg dosage offers an effective starting dose for patients requiring moderate lipid reduction, with dose adjustments based on therapeutic response and tolerability. Common adverse effects may include headache, myalgia, and gastrointestinal disturbances, while serious side effects such as myopathy and hepatotoxicity are rare but warrant monitoring. Regular lipid profile assessments and liver function tests are recommended during therapy to ensure efficacy and safety.